Raising guidance in this economy? Boston Scientific just did it.

The Maple Grove City Council recently approved a planned expansion costing $139.4 million, according to city documents. The company expects to create 440 new full-time equivalent jobs by 2030, the documents say.

For the first quarter, Boston Scientific reported $1.12 billion in adjusted profit on $4.6 billion in sales, beating Wall Street profit estimates. Sales grew on an organic basis by 18.2%.

During the quarter, the company passed the 10-year anniversary of the Watchman device’s approval. An independent company created this heart plug device preventing stroke-causing blood clots, and Boston Scientific further developed it in Minnesota.

The device franchise grew 24% for the quarter after the company’s market share increased, Mahoney said. Strong uptake in patients receiving the device and undergoing transcatheter aortic valve replacement at the same time, referred to as a concomitant procedure, drove the uptake.

“We’re seeing very strong adoption of the concomitant, based on the safety profile, ease of use, the benefits for the hospital, the benefits of the patient, the physician,” Mahoney said. “It’s great to see the stars aligned to doing the right thing for the patient — the right thing for the hospital system.”

Urology sales were the slowest out of the company’s four largest divisions, increasing by 4.4% organically. Mahoney said this is “a tad under what we’re used to.”